We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

191 hedge funds and large institutions have $2.43B invested in GW Pharmaceuticals Plc American Depositary Shares in 2018 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 69 increasing their positions, 46 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 46

6% less funds holding

Funds holding: 204191 (-13)

20% less capital invested

Capital invested by funds: $3.03B → $2.43B (-$599M)

29% less call options, than puts

Call options by funds: $83.6M | Put options by funds: $118M

33% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 39

67% less funds holding in top 10

Funds holding in top 10: 62 (-4)

Holders
191
Holders Change
-13
Holders Change %
-6.37%
% of All Funds
4.38%
Holding in Top 10
2
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-66.67%
% of All Funds
0.05%
New
26
Increased
69
Reduced
46
Closed
39
Calls
$83.6M
Puts
$118M
Net Calls
-$34.6M
Net Calls Change
-$24.5M
Name Holding Trade Value Shares
Change
Change in
Stake
UBS AM
176
UBS AM
Illinois
$3.38K +$3.77K +30 New
CFA
177
Carroll Financial Associates
North Carolina
$3K
Fifth Third Bancorp
178
Fifth Third Bancorp
Ohio
$3K
HDIM
179
Hanson & Doremus Investment Management
Vermont
$3K
PA
180
Parallel Advisors
California
$3K
Bessemer Group
181
Bessemer Group
New Jersey
$2K
FBT
182
First Bank & Trust
South Dakota
$2K
GI
183
Gradient Investments
Minnesota
$2K
KIG
184
Kessler Investment Group
Indiana
$2K
WAS
185
Winch Advisory Services
Wisconsin
$2K
WA
186
WealthTrust-Arizona
Arizona
$1K
Viking Global Investors
187
Viking Global Investors
Connecticut
-$28M -211,869 Closed
TCP
188
Tourbillon Capital Partners
New York
-$18.7M -148,327 Closed
MWNA
189
Marshall Wace North America
New York
-$13.9M -105,250 Closed
GPP
190
Great Point Partners
Connecticut
-$9.9M -75,000 Closed
Capital Fund Management (CFM)
191
Capital Fund Management (CFM)
France
-$6.76M -51,236 Closed
RI
192
Redwood Investments
Massachusetts
-$6.58M -49,853 Closed
AC
193
Ascend Capital
California
-$5.18M -39,216 Closed
ACM
194
Atika Capital Management
New York
-$4.09M -31,000 Closed
SGH
195
Sivik Global Healthcare
Connecticut
-$3.96M -30,000 Closed
QIM
196
Quantitative Investment Management
Virginia
-$3.85M -29,200 Closed
SCM
197
Sio Capital Management
New York
-$2.51M -19,000 Closed
CLCM
198
Crawford Lake Capital Management
New Jersey
-$2.24M -17,000 Closed
Renaissance Technologies
199
Renaissance Technologies
New York
-$2.22M -16,820 Closed
VF
200
Virtu Financial
New York
-$2.1M -15,893 Closed

GWPH Hedge Fund Activity: Q1 2018 in Review

191 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q1 2018, worth a combined $2.43B — down 20% from $3.03B a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of GWPH and 26 opened new positions — a net loss of 13 holders — while 46 trimmed existing stakes and 69 added.

The largest buyer was Capital World Investors, adding an estimated $93.7M. The largest seller was Scopia Capital Management, cutting an estimated $93M.

  • 191 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q1 2018, down from 204 in Q4 2017.
  • Funds reported $2.43B of GW Pharmaceuticals Plc American Depositary Shares stock for Q1 2018, down 20% quarter-over-quarter.
  • 26 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q1 2018 and 39 closed out, a net change of -13 holders.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q1 2018 was Capital World Investors, an estimated $93.7M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q1 2018 was Scopia Capital Management, an estimated $93M sold.

Based on aggregated 13F filings for Q1 2018.